BRIEF published on 08/14/2025 at 07:05, 7 months 12 days ago Relief Therapeutics Releases 2025 Half-Year Report Relief Therapeutics RLF-TD011 RLF-OD032 2025 Half-Year Report NeuroX Partnership
PRESS RELEASE published on 08/14/2025 at 07:00, 7 months 12 days ago Relief Therapeutics Publishes 2025 Half-Year Report Relief Therapeutics published its 2025 half-year report, highlighting progress in pipeline candidates for rare diseases and financial status. Corporate update includes advances in wound care and liquid formulation for phenylketonuria Financial Status Relief Therapeutics Rare Diseases 2025 Half-Year Report Pipeline Candidates
BRIEF published on 08/11/2025 at 07:05, 7 months 15 days ago Relief Therapeutics Advances 2025 Half-Year Report Publication Biopharmaceutical Company Relief Therapeutics Innovative Treatments Geneva Half-Year Report 2025
PRESS RELEASE published on 08/11/2025 at 07:00, 7 months 15 days ago Relief Therapeutics Advances Publication of 2025 Half-Year Report Relief Therapeutics advances publication of its 2025 half-year report from August 27 to August 14, 2025, indicating completion ahead of schedule. Company to provide shareholder update and financial statements Biopharmaceutical Relief Therapeutics Publication Innovative Treatment Options 2025 Half-Year Report
BRIEF published on 07/29/2025 at 07:05, 7 months 28 days ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
PRESS RELEASE published on 07/29/2025 at 07:00, 7 months 28 days ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 9 months 6 days ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
PRESS RELEASE published on 06/20/2025 at 07:00, 9 months 6 days ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 9 months 14 days ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
PRESS RELEASE published on 06/12/2025 at 11:00, 9 months 14 days ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
Published on 03/26/2026 at 13:00, 3 hours 22 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 3 hours 22 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 3 hours 23 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 3 hours 37 minutes ago Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia
Published on 03/26/2026 at 15:25, 57 minutes ago Duck Creek Loss Control Named 2026 Insurance Luminary Finalist by PropertyCasualty360
Published on 03/26/2026 at 15:23, 58 minutes ago Sartorius AG - Resolutions of the Annual General Meeting
Published on 03/26/2026 at 15:05, 1 hour 17 minutes ago JOY GROUP Announces 2025 Financial Results, Revenue Surpasses US$620M
Published on 03/26/2026 at 15:01, 1 hour 20 minutes ago EQS-Adhoc: CENIT AG decides to switch from the Regulated Market (Prime Standard) to the Scale Segment of the Frankfurt Stock Exchange
Published on 03/26/2026 at 15:00, 1 hour 22 minutes ago OLB’s financial performance remains at a consistently high level
Published on 03/26/2026 at 07:30, 8 hours 52 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:31, 21 hours 51 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 22 hours 37 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
